Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4

Kidney International, Supplement

Volumn 63, Issue 85, 2003, Pages

  Coburn, Jack W ^a,b   Maung, Hla M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b West Los Angeles Veterans Health Care Center   (United States)

Author keywords

Alfacalcidol; Bone density; Calcitriol; Doxercalciferol; Guidelines; Hypercalcemia; Mild to moderate renal insufficiency; Secondary hyperparathyroidism; Treatment

Indexed keywords

ALFACALCIDOL; CALCITRIOL; DOXERCALCIFEROL; PARATHYROID HORMONE; STEROL DERIVATIVE; VITAMIN D;

BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE DISEASE; BONE MINERAL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SECONDARY HYPERPARATHYROIDISM; SOFT TISSUE CALCIFICATION; VITAMIN SUPPLEMENTATION;

EID: 0037512524     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s85.12.x     Document Type: Conference Paper

References (22)

1. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 39(Suppl. 1):S1-S266, 2002
2. STEDDON S J, SCHROEDER NJ, CUNNINGHAM J: Vitamin D analogues: How do they differ and what is their clinical use. Nephrol Dial Transplant 16:1965-]967, 2001
3. 3 in the correction and prevention of renal osteodystrophy in patients with mild to moderate renal failure, in Vitamin D: A Chemical, Biochemical and Clinical Update, edited by NORMAN AW, SCHAEFER K. GRIGOLEIT H-G, et al, Berlin, de Gruyter, 1985, pp 935-937
4. NORDAL KP, DAHL E: Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 67:929-936, 1988
5. 3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35:661-669, 1989
6. PRZEDLACKI J, MANELIUS J, HUTTUNEN K: Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Nephron 69:433-437, 1995
7. RITZ E, KÜSTER S, SCHMIDT-GAYK H, et al: Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 10: 2228-2234, 1995
8. HAMDY NAT, KANIS JA, BENETON MNC, et al: Effect of alfacalcidol on natural course of bone disease in mild to moderate renal failure. BMJ 310:358-363, 1995
9. RIX M: Metabolic bone disease in patients with predialysis chronic renal failure. Copenhagen, University of Copenhagen, 1999, p 1-84
10. 3) for 2° hyperparathyroidism in chronic kidney disease (CKD). Nephrol Dial Transplant 17(Suppl 1):7, 2002
11. 3: Humoral and histomorphometric results. Miner Electrolyte Metab 12:375-382, 1986
12. BIANCHI ML, COLANTONIO G, CAMPANINI F, et al: Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 9:1595-1599, 1994
13. BERTOLI M, LUISETTO G, RUFFATTI A, et al: Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 33:98-102, 1990
14. NORDAL KP, DAHL E, HALSE J, et al: Long-term low-dose calcitriol in predialysis chronic renal failure: Can it prevent hyperparathyroid bone disease? Nephrol Dial Transplant 10:203-206, 1995
15. PANICHI V. ANDREINI B, DE PIETRO S, et al: Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Clin Nephrol 49:245-250, 1998
16. QUARLES LD, LOBAUGH B, MURPHY G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145-150, 1992
17. SHERRARD DJ, HERCZ G, PEI Y, et al: The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int 43: 436-442, 1993
18. HERNANDEZ D, CONCEPCION MT, LORENZO V, et al: Adynamic bone disease with negative aluminum staining in predialysis patients: Prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 9:517-523, 1994
19. 3 in predialysis chronic renal failure may lower the rate of decline of renal function. Ital J Miner Electrolyte Metab 8:117-121, 1994
20. 3 and renal function. Acta Med Scand 211:51-54, 1982
21. 3) for the treatment of psoriasis. Br J Derm 134:1070-1078, 1996
22. CHERTOW GM, BURKE SK, RAGGI P, Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002